Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclatasvir in HCV Genotype 1
NCT00663208Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2008
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of daclatasvir in hepatitis C (HCV) (7 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Change From Baseline in log10 Hepatitis C Virus (HCV) RNA at Day 7. Started May 2008; status: completed.
02
Drugs
daclatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00663208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00663208.